NCT02622581Recruiting
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 14500 (estimated)
- First submitted
- 2 Dec 2015
- Start date
- Dec 2015
- Primary completion date
- Sept 2030
- Lead sponsor
- AIO-Studien-gGmbH
- Diseases
- Lung cancer
- NCT number
- NCT02622581
What you commit to
- Study type: Observational
- Planned participants: 14500
- From Dec 2015 to the primary completion date, Sept 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- none
Who the study is looking for
- Patients who meet all of the following criteria are eligible for the project:
- Age ≥ 18 years
- Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments
- Main project (NSCLC Stage IV):
- Confirmed non-small cell lung cancer (NSCLC)
- Stage IV (UICC8)
- Systemic therapy
- Informed consent no later than four weeks after start of first-line systemic treatment
- Satellite NSCLC Stage I-III:
- Confirmed non-small cell lung cancer (NSCLC)
- Informed consent no later than four weeks after start of first anti-tumor treatment (including surgery and radiotherapy) or if first treatment is surgery no longer than 3 months after start of surgery.
- Stage I-III (UICC8)
- Systemic (chemo)therapy and/or radiation therapy and/or surgery
- Satellite SCLC
- Confirmed Small cell lung cancer (SCLC)
- Informed consent no later than four weeks after start of first anti-tumor treatment
- Systemic (chemo)therapy and/or radiation therapy and/or surgery
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pius-Hospital Coordinator of this site? Confirm its status | Oldenburg | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.